Cardlytics (CDLX) Common Equity (2017 - 2026)

Cardlytics' Common Equity history runs 10 years deep, the most recent figure standing at -$4.0 million for Q1 2026.

• Quarterly Common Equity fell 106.25% year-over-year to -$4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.0 million (down 106.25% YoY) and the FY2025 annual result came in at -$6.5 million, down 109.3% from the prior year.
• Common Equity was -$4.0 million for Q1 2026 at Cardlytics, up from -$6.5 million in the prior quarter.
• Across five years, Common Equity topped out at $711.7 million in Q1 2022 and bottomed at -$6.5 million in Q4 2025.
• A 5-year average of $209.0 million and a median of $199.1 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity declined 4.46% — and 2025, when it slumped 109.3%.
• Cardlytics' Common Equity stood at $211.6 million in 2022, then slumped by 36.3% to $134.8 million in 2023, then sank by 48.08% to $70.0 million in 2024, then slumped by 109.3% to -$6.5 million in 2025, then soared by 38.49% to -$4.0 million in 2026.
• Business Quant data shows CDLX's Common Equity at -$4.0 million in Q1 2026, -$6.5 million in Q4 2025, and -$4.7 million in Q3 2025.